Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China
نویسندگان
چکیده
منابع مشابه
The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...
متن کاملpharmacotherapy updates of recombinant tissue plasminogen activator (r-tpa) in acute ischemic stroke
conclusions due to considerable inter- and intra- heterogeneity among studies performed by other centers such as differences in study project, background, and population features, determining a pharmacotherapy model based on safe implementation of treatments in stroke or sits seem advantageous. results age, time of onset, systolic blood pressure, diabetes, stroke severity, co-morbidities and pr...
متن کاملUsing recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).
BACKGROUND AND PURPOSE Little is known about intravenous recombinant tissue plasminogen activator (rtPA) use in China. By accessing the Chinese National Stroke Registry (CNSR), the rate of intravenous rtPA use was reviewed. We specifically examined the issues of prehospital and in-emergency department delay and compared them with the published data from developed countries. METHODS Funded by ...
متن کاملRecombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke
THE FOOD AND DRUG ADMINIStration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials (1 and...
متن کاملAge-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
INTRODUCTION Studies have demonstrated that intravenous recombinant tissue plasminogen activator (IV rtPA) is a cost-effective treatment for acute ischemic stroke. Age-specific cost effectiveness has not been well examined. This study estimated age-specific incremental cost-effectiveness ratios (ICERs) of IV rtPA treatment versus no IV rtPA. METHODS A Markov model was developed to examine the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2011
ISSN: 0039-2499,1524-4628
DOI: 10.1161/strokeaha.110.604249